A real-world multicenter study on postoperative adjuvant treatment patterns and prognostic implications following neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma
For ESCC patients receiving nICT, postoperative adjuvant treatment can provide survival benefits, particularly more pronounced in non-pCR patients and those with advanced postoperative pathological stages, particularly more pronounced in non-pCR patients and those with advanced postoperative pathological stages.